364 related articles for article (PubMed ID: 18798058)
1. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
2. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
4. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
5. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
Lackner MR
Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
[TBL] [Abstract][Full Text] [Related]
6. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
9. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
Zhu YJ; Jiang FC
Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
[TBL] [Abstract][Full Text] [Related]
10. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
11. Raf pathway inhibitors in oncology.
Bollag G; Freeman S; Lyons JF; Post LE
Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
[TBL] [Abstract][Full Text] [Related]
12. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
13. Novel inhibitors of the PI3K family.
Carnero A
Expert Opin Investig Drugs; 2009 Sep; 18(9):1265-77. PubMed ID: 19589091
[TBL] [Abstract][Full Text] [Related]
14. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
15. New druggable targets in the Ras pathway?
Matallanas D; Crespo P
Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
[TBL] [Abstract][Full Text] [Related]
16. Cancer targets in the Ras pathway.
Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
[TBL] [Abstract][Full Text] [Related]
17. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
18. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
19. Chemical biology of lipidated proteins.
Triola G; Waldmann H; Hedberg C
ACS Chem Biol; 2012 Jan; 7(1):87-99. PubMed ID: 22148864
[TBL] [Abstract][Full Text] [Related]
20. The ras signalling pathway as a target in cancer therapy.
Graham K; Olson MF
Recent Results Cancer Res; 2007; 172():125-53. PubMed ID: 17607939
[No Abstract] [Full Text] [Related]
[Next] [New Search]